Application of CD45 as biomarker in screening effectiveness and accuracy of CD26 antibody or derivative thereof in tumor treatment

The invention relates to application of CD45 as a biomarker in screening effectiveness of a subject on tumor treatment of a CD26 antibody or a derivative thereof. Specifically, when the CD45 does not express or is low in expression, it is judged that the treatment of the subject receiving the CD26 antibody or the derivative thereof is effective or the effective probability is high, and when the CD45 is high in expression or relatively high in expression, it is judged that the treatment of the subject receiving the CD26 antibody or the derivative thereof is ineffective or the ineffective probability is high. According to the application, the biomarker capable of effectively screening the tumor treatment effectiveness of the CD26 antibody or the derivative thereof is screened out, the tumor treatment accuracy and effectiveness of the CD26 antibody or the derivative thereof can be remarkably improved, and the clinical benefit of a patient is improved; a new mechanism of treatment effectiveness and accuracy of th